ENPICOM, a bioinformatics software solutions provider, will collaborate with Erasmus Medical Center, Rotterdam, to identify and develop nanobodies against cancer by utilizing ENPICOM’s immune repertoire data analysis services and software solutions.
CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single- and multi-organ microphysiological systems (MPS), has appointed Joseph Parisi as US Director of Sales. In his new role, Parisi will lead the expansion of the company’s sales and support activities for the US market to address the growing demand for new alternative methodologies […]
The biotech company Pluri has launched a new business division offering cell therapy manufacturing services as a Contract Development and Manufacturing Organization (CDMO): PluriCDMO.
The Clinical and Laboratory Standards Institute (CLSI) has implemented new Country-Based Pricing
Vetter, a globally operating contract development and manufacturing organization (CDMO), has joined the German Association of Research-Based Pharmaceutical Companies (vfa) as an associate member. With this membership, the vfa recognizes the significant role that the pharmaceutical service provider plays in the field of complex injectable drugs.
Australian, European and U.S. clients are now able to tap into world-class strategic advice and full-service clinical trial capabilities following the announcement of Biointelect’s and CR2O’s new strategic partnership.
Capricorn Scientific and ExcellGene have established a strategic partnership within the biotechnology sector. Applying their collective expertise and capabilities, the collaboration seeks to help customers by optimizing processes, developing products, and offering solutions in biotechnology. The partnership is dedicated to customeroriented solutions and a commitment to excellence, with the aim of advancing biotech research, development, […]
PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease (AD) and other neurodegenerative diseases, will collaborate with Sheffield Hallam University in the field of epigenetics. The partnership will focus on ‘gene-based environmental biomarkers’ – epigenetic markers – for calculating risk scores for Alzheimer’s diseases. Together with PharmaKure’s blood-based biomarker, ALZmetrix https://bitly.ws/3eZTQ, this […]
Johnson & Johnson has entered into a definitive agreement to acquire Ambrx Biopharma, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2 billion, or $1.9 billion net of estimated cash acquired.
Getting the most from every drop – new advances in blood separation Alexandra Sommer, Senior Product Manager, Clinical Diagnostics at Tecan
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
